Hydroxychloroquine, a PPT1 inhibitor, has been shown to target PPT1 and increases AEG-1 palmitoylation levels, thereby inhibiting the growth of HCC cells [33]. The gene discussed is MTDH; the disease is hepatocellular carcinoma.